Charles D. Hyman’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $4.21M | Sell |
150,341
-4,972
| -3% | -$137K | 0.23% | 68 |
|
|
2024
Q1 | $4.31M | Buy |
155,313
+3,427
| +2% | +$95.1K | 0.24% | 67 |
|
|
2023
Q4 | $4.37M | Sell |
151,886
-1,092
| -0.7% | -$33K | 0.26% | 65 |
|
|
2023
Q3 | $5.07M | Sell |
152,978
-921
| -0.6% | -$32.6K | 0.33% | 54 |
|
|
2023
Q2 | $5.64M | Sell |
153,899
-50
| -0% | -$1.95K | 0.35% | 52 |
|
|
2023
Q1 | $6.28M | Sell |
153,949
-600
| -0.4% | -$25.9K | 0.42% | 48 |
|
|
2022
Q4 | $7.92M | Hold |
154,549
| – | – | 0.54% | 44 |
|
|
2022
Q3 | $6.76M | Sell |
154,549
-4,396
| -3% | -$214K | 0.52% | 44 |
|
|
2022
Q2 | $8.33M | Sell |
158,945
-1,372
| -0.9% | -$69.9K | 0.61% | 43 |
|
|
2022
Q1 | $8.3M | Buy |
160,317
+3,400
| +2% | +$176K | 0.52% | 46 |
|
|
2021
Q4 | $9.27M | Buy |
156,917
+7,183
| +5% | +$356K | 0.59% | 44 |
|
|
2021
Q3 | $6.44M | Sell |
149,734
-289
| -0.2% | -$12.8K | 0.45% | 51 |
|
|
2021
Q2 | $5.88M | Sell |
150,023
-2,035
| -1% | -$79.1K | 0.41% | 52 |
|
|
2021
Q1 | $5.51M | Sell |
152,058
-407
| -0.3% | -$14.5K | 0.4% | 54 |
|
|
2020
Q4 | $5.61M | Sell |
152,465
-10,782
| -7% | -$395K | 0.45% | 48 |
|
|
2020
Q3 | $5.68M | Buy |
163,247
+9,796
| +6% | +$343K | 0.5% | 44 |
|
|
2020
Q2 | $4.76M | Buy |
153,451
+20,519
| +15% | +$697K | 0.46% | 49 |
|
|
2020
Q1 | $4.12M | Sell |
132,932
-2,936
| -2% | -$100K | 0.52% | 47 |
|
|
2019
Q4 | $5.05M | Buy |
135,868
+2,700
| +2% | +$96.2K | 0.5% | 51 |
|
|
2019
Q3 | $4.54M | Sell |
133,168
-2,307
| -2% | -$83.9K | 0.47% | 53 |
|
|
2019
Q2 | $5.57M | Buy |
135,475
+734
| +0.5% | +$29.1K | 0.58% | 49 |
|
|
2019
Q1 | $5.43M | Buy |
134,741
+19,508
| +17% | +$781K | 0.56% | 50 |
|
|
2018
Q4 | $4.77M | Sell |
115,233
-2,170
| -2% | -$90.1K | 0.57% | 51 |
|
|
2018
Q3 | $4.91M | Buy |
117,403
+558
| +0.5% | +$21.5K | 0.51% | 54 |
|
|
2018
Q2 | $4.02M | Sell |
116,845
-1,074
| -0.9% | -$36.7K | 0.45% | 61 |
|
|
2018
Q1 | $3.97M | Sell |
117,919
-1,656
| -1% | -$56.9K | 0.46% | 61 |
|
|
2017
Q4 | $4.11M | Buy |
119,575
+538
| +0.5% | +$18.3K | 0.47% | 58 |
|
|
2017
Q3 | $4.03M | Sell |
119,037
-8,743
| -7% | -$281K | 0.5% | 57 |
|
|
2017
Q2 | $4.07M | Sell |
127,780
-1,699
| -1% | -$53.6K | 0.52% | 56 |
|
|
2017
Q1 | $4.2M | Sell |
129,479
-72
| -0.1% | -$2.27K | 0.56% | 54 |
|
|
2016
Q4 | $3.99M | Sell |
129,551
-5,892
| -4% | -$180K | 0.56% | 52 |
|
|
2016
Q3 | $4.35M | Sell |
135,443
-2,340
| -2% | -$78.2K | 0.65% | 49 |
|
|
2016
Q2 | $4.6M | Buy |
137,783
+8,677
| +7% | +$277K | 0.69% | 48 |
|
|
2016
Q1 | $3.63M | Sell |
129,106
-469
| -0.4% | -$13.4K | 0.57% | 53 |
|
|
2015
Q4 | $3.97M | Sell |
129,575
-12,375
| -9% | -$389K | 0.65% | 50 |
|
|
2015
Q3 | $4.23M | Sell |
141,950
-413
| -0.3% | -$13.2K | 0.74% | 47 |
|
|
2015
Q2 | $4.53M | Sell |
142,363
-96
| -0.1% | -$3.13K | 0.73% | 48 |
|
|
2015
Q1 | $4.7M | Buy |
142,459
+618
| +0.4% | +$19.6K | 0.75% | 48 |
|
|
2014
Q4 | $4.19M | Sell |
141,841
-1,014
| -0.7% | -$29.1K | 0.68% | 49 |
|
|
2014
Q3 | $4.01M | Sell |
142,855
-3,849
| -3% | -$108K | 0.67% | 49 |
|
|
2014
Q2 | $4.13M | Sell |
146,704
-1,830
| -1% | -$52.2K | 0.7% | 49 |
|
|
2014
Q1 | $4.53M | Buy |
148,534
+703
| +0.5% | +$21K | 0.82% | 47 |
|
|
2013
Q4 | $4.3M | Sell |
147,831
-1,844
| -1% | -$53.7K | 0.79% | 47 |
|
|
2013
Q3 | $4.08M | Sell |
149,675
-18
| -0% | -$490 | 0.81% | 46 |
|
|
2013
Q2 | $3.98M | Buy |
+149,693
| New | +$4.14M | 0.82% | 46 |
|
Other funds holding PFE
Charles D. Hyman's PFE Position: Q2 2024 in Review
Charles D. Hyman reduced its Pfizer (PFE) stake by 3.2% in Q2 2024, selling an estimated $137K and leaving 150,341 shares worth $4.21M. The position accounts for 0.23% of the portfolio, ranked #68.
Charles D. Hyman first reported a position in PFE in Q2 2013 and has held it in 45 quarters since. The position peaked at $9.27M in Q4 2021. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Charles D. Hyman held 150,341 shares of Pfizer worth $4.21M as of Q2 2024.
- Charles D. Hyman sold 4,972 Pfizer shares in Q2 2024, an estimated $137K.
- Pfizer made up 0.23% of Charles D. Hyman's portfolio in Q2 2024, its #68 holding.
- Charles D. Hyman first reported a position in Pfizer in Q2 2013 and has held it in 45 quarters since.
- Charles D. Hyman's Pfizer position peaked at $9.27M in Q4 2021.
- 2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Charles D. Hyman's 13F filing for Q2 2024, filed 25 Jul 2024.